Chimerix, Inc. (CMRX)
| Market Cap | 501.20M |
| Revenue (ttm) | 3.05M |
| Net Income (ttm) | -145.41M |
| Shares Out | 86.86M |
| EPS (ttm) | -1.84 |
| PE Ratio | n/a |
| Forward PE | 227.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,342 |
| Open | 5.92 |
| Previous Close | 5.62 |
| Day's Range | 5.77 - 5.77 |
| 52-Week Range | 4.75 - 11.57 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 18.67 (+223.6%) |
| Earnings Date | Nov 4, 2021 |
About CMRX
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Chimerix stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 223.57% from the latest price.
News
Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer...
DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Soc...
– Plenary Session Presentation on Saturday, November 20 –
Chimerix to Present at Jefferies London Healthcare Conference
DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fac...
Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix Shares Brain Cancer Trial Data
Chimerix Inc (NASDAQ: CMRX) has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer). ONC201 is an orally admin...
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update
– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –
Analysts Estimate Chimerix (CMRX) to Report a Decline in Earnings: What to Look Out for
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their ...
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and pa...
Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today ...
Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –
Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?
Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon
Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix Appoints Vicki Vakiener to Board of Directors
DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Re...
WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung disease...
Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study
Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The...
Steven Cohen Dives Into Chimerix
Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...